Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | FABP3 | P05413 | 1/20 | 0.30 |
| ▸ | FABP4 | P15090 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2299273 | 0.81 | ROCK2 (0.34) | GABRA1GABRB2FABP3FABP4CYP1A2 | |
| SCHEMBL29382588 | 0.79 | ROCK2 (0.35) | GABRA1GABRB2FABP3FABP4CYP1A2 | |
| SCHEMBL30317598 | 0.74 | ROCK2 (0.39) | GABRA1GABRB2FABP3FABP4CYP1A2 | |
| Hydrochloric Acid SCHEMBL21331878 | 0.73 | ROCK2 (0.38) | GABRA1GABRB2FABP3FABP4CYP1A2 | |
| SCHEMBL2484888 | 0.71 | GABRA1 (0.31) | GABRA1GABRB2FABP3FABP4CYP1A2 | |
| SCHEMBL646869 | 0.70 | GABRA1 (0.39) | GABRA1GABRB2 | |
| SCHEMBL19619459 | 0.69 | GABRA1 (0.46) | GABRA1GABRB2FABP3FABP4CYP1A2 | |
| SCHEMBL16241800 | 0.68 | GABRA1 (0.31) | GABRA1GABRB2FABP3FABP4 | |
| SCHEMBL29496244 | 0.67 | — | — | |
| SCHEMBL30135690 | 0.66 | ALDH1A1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092784-A1 | CONDENSED HETEROCYCLIC COMPOUND | NISSAN CHEMICAL CORPORATION (JP) | 2024-03-21 | — | — | US | disclosed |
| EP-4219500-A1 | CONDENSED HETEROCYCLIC COMPOUND | Nissan Chemical Corporation (JP) | 2023-08-02 | — | — | EP | disclosed |
| CN-116120320-A | Intermediate for substituted tricyclic PRMT5 inhibitor and preparation method thereof | 南京汇诚制药有限公司 | 2023-05-16 | — | — | CN | disclosed |
| EP-3368514-B1 | TRISUBSTITUTED SILYLPHENOXYHETEROCYCLES AND ANALOGUES | BAYER CROPSCIENCE AG (DE) | 2021-08-18 | — | — | EP | disclosed |
| US-10683311-B2 | Trisubstitutedsilylphenoxyheterocycles and analogues | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2020-06-16 | — | — | US | disclosed |
| US-20190233444-A1 | TRISUBSTITUTEDSILYLPHENOXYHETEROCYCLES AND ANALOGUES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2019-08-01 | — | — | US | disclosed |
| US-9433626-B2 | Pyrido[4,3-B]indole and pyrido[3,4-B]indole derivatives and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| CN-105683196-A | Aryl ether based kinase inhibitors | 百时美施贵宝公司 | 2016-06-15 | — | — | CN | disclosed |
| US-20150335654-A1 | PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2015-11-26 | — | — | US | disclosed |
| US-9193728-B2 | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| WO-2012168162-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | disclosed |
| US-20120309796-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | FIROOZNIA FARIBORZ (US) | 2012-12-06 | — | — | US | disclosed |
| WO-2012009617-A3 | METHODS, STORAGE MEDIUMS, AND SYSTEMS FOR ANALYZING PARTICLE QUANTITY AND DISTRIBUTION WITHIN AN IMAGING REGION OF AN ASSAY ANALYSIS SYSTEM AND FOR EVALUATING THE PERFORMANCE OF A FOCUSING ROUTING PERFORMED ON AN ASSAY ANALYSIS SYSTEM | LUMINEX CORPORATION (US) | 2012-05-10 | — | — | WO | disclosed |
| EP-2271617-B1 | SUBSTITUTED 4-HYDROXY-N- (4-HYDROXYPHENYL) INDOLES AS ESTROGENIC AGENTS | GLAXO GROUP LTD (GB) | 2011-11-30 | — | — | EP | disclosed |
| EP-2222668-B1 | TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARM INC (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2035436-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100273806-A1 | TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| WO-2009050235-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
| EP-2035436-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008001076-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683311-B2 | Trisubstitutedsilylphenoxyheterocycles and analogues | PIK3C3, ERG28, DDT | GABRA1 2099/4885GABRB2 1580/4885FABP3 4739/4885 |
| US-20240092784-A1 | CONDENSED HETEROCYCLIC COMPOUND | SPR, QDPR, SUCNR1 | GABRA1 3432/4885GABRB2 3331/4885FABP3 4494/4885 |
| US-20100273806-A1 | TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR3, S1PR2 | GABRA1 751/4885GABRB2 1678/4885FABP3 1410/4885 |
| US-20190233444-A1 | TRISUBSTITUTEDSILYLPHENOXYHETEROCYCLES AND ANALOGUES | PIK3C3, ERG28, DDT | GABRA1 2099/4885GABRB2 1580/4885FABP3 4739/4885 |
| US-20150335654-A1 | PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | HTR3B, HTR4, HTR2C | GABRA1 251/4885GABRB2 166/4885FABP3 3443/4885 |
| US-20120309796-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | ACAT2, ACAT1, CYP27A1 | GABRA1 219/4885GABRB2 232/4885FABP3 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.